Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Biospectal Selected as One of Ten Finalists for the “Saving Lives at Birth” 2018 Grand Challenge

Biospectal was recently selected from more than five hundred applicants to present with our partner team at the Saving Lives at Birth Global Grand Challenge DEVELOPMENTxCHANGE conference in Washington, D.C. Saving Lives at Birth is focused on identifying and scaling transformative prevention and treatment approaches for pregnant women and newborns. It brings together the U.S. Agency for International Development (USAID), the Government of Norway (Norad), the Bill and Melinda Gates Foundation, Grand Challenges Canada, the U.K. Department of International Development (DFID), and the Korea International Cooperation Agency (KOICA).

The team’s proposal is to support an independent field validation study through One Kenya, Limited, and the World Health Organization to integrate the Biospectal’s smartphone based optical blood pressure solution with World Health Organization’s OpenSRP electronic medical record and longitudinal decision support and patient record system in Tanzania and Indonesia. This will serve as a springboard for wider deployment across sites supporting maternal health in low and low to middle income countries.

”We are thrilled to be able to bring our software technology to a global setting for low resource populations,” said Dr. Patrick Schoettker, co-founder and father of Biospectal’s optical blood pressure vision. “We are intent on democratizing diagnostic sensing for a global population. It’s exciting and core to our mission as co-founders to make a global impact and to enable improvement of the standard of care for all populations. Smartphones are everywhere in the world, and we can piggy back on that technology enable hypertension management with a device people already have in their pocket.”

Biospectal will be joining other current innovators working with Saving Lives at Birth, including the nine other finalists and ten award recipients selected previously in Round 8.

For more information, see: https://savinglivesatbirth.net/blog/18/04/20/save-date-saving-lives-birth-developmentxchange-2018